Key facts
- AbbVie Inc. is reportedly close to acquiring Apogee Therapeutics Inc.
- The potential deal is valued at nearly $11 billion in cash.
- The acquisition is intended to enhance AbbVie's anti-inflammatory drug offerings.
AbbVie Inc. is reportedly in the final stages of a deal to acquire Apogee Therapeutics Inc. for approximately $11 billion in cash. The move is intended to expand AbbVie's range of anti-inflammatory medications. The Financial Times reported on the impending transaction.